Actively Recruiting
Study of 1-Year Dual Antiplatelet Therapy After GENOSS Sirolimus Eluting Stent for Coronary Artery Disease in High-Risk Patients
Led by Genoss Co., Ltd. · Updated on 2025-02-21
1000
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of using dual antiplatelet therapy DAPT for one year following implantation of the GENOSS sirolimus eluting stent DES in patients with coronary artery disease who undergo complex higher-risk procedures. This prospective, multicenter observational study aims to provide real-world clinical outcomes data, focusing on patients treated at nine sites in South Korea. The study measures cardiac-related events such as death, myocardial infarction, and the need for repeat procedures at 12 months after stent placement. The study involves patients receiving the GENOSS DES, a novel biodegradable polymer-coated stent with a cobalt-chromium platform and thin struts. Participants are selected based on clinical and lesion-related risk factors that define complex higher-risk procedures. These include age 75 or older, diabetes, kidney disease, history of stroke or bypass surgery, left ventricular dysfunction, severe valve disease, acute coronary syndrome, and specific lesion characteristics such as left main lesion, chronic total occlusion, bifurcation lesions, calcified or restenosis lesions, multivessel percutaneous coronary intervention, multiple stents, or long stent length. Patients will be observed under standard care with 1 year of DAPT after the GENOSS stent implantation. During the study, participants will be monitored for device-oriented outcomes including cardiac death, target vessel myocardial infarction, and target lesion revascularization at 12 months. Additional outcomes such as all-cause death, any myocardial infarction, and any revascularization will also be assessed. The study collects clinical follow-up data and evaluates procedural success immediately after stent placement. Participation involves regular clinical assessments over the course of one year to track safety and efficacy outcomes related to the stent and DAPT treatment.
CONDITIONS
Brief Title
Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure
Research Team
Y
YoungJin Youn
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here